Adrenergic Receptors: Where They Live, What They Do

Tempting to pick beta-1 (raises HR and contractility): when BP crashes, boosting the pump seems right. The trap is that anaphylaxis is not pump failure, it is pipe pressure failure. Think of the cardiovascular system as a water pressure system: the pump (heart, beta-1) is fine, but the pipes dilated all at once from histamine. Alpha-1 squeezes the pipes back. Running the pump harder without fixing the pipe pressure only wastes effort. C is correct. Anaphylactic shock = massive histamine-induced vasodilation → BP crashes because SVR (systemic vascular resistance) collapses. α1-mediated vasoconstriction directly reverses this: contracts vascular smooth muscle → raises SVR → raises BP. β2 bronchodilation is also critical (fixes the stridor) but the life-threatening hypotension is the vasodilation problem. Break it down: Anaphylaxis hypotension = histamine vasodilation → α1 vasoconstriction from Epi = direct fix. β2 fixes the bronchoconstriction concurrently. Both needed, α1 is the BP answer.

Tempting to pick propranolol: it is the most famous beta-blocker with excellent post-MI data. The trap is that propranolol is non-selective and its B2 block in COPD bronchi triggers bronchospasm. Think of cardioselective beta-blockers as a precision screwdriver that fits only the B1 cardiac screws while leaving the B2 bronchodilator screws in the lung untouched. Non-selective agents hit both sets of screws. B is correct. Metoprolol, atenolol, and bisoprolol are cardioselective β1-blockers. Lung bronchi use β2 receptors. By preferentially blocking β1 (heart), cardioselective blockers have much less bronchospasm risk. Note: selectivity is dose-dependent · at high doses even metoprolol blocks β2. "Safer" not "safe." Break it down: COPD/asthma + beta-blocker needed = β1-selective (metoprolol, atenolol, bisoprolol, esmolol). Non-selective (propranolol, nadolol, sotalol, timolol) block β2 → bronchospasm.

Tempting to pick B1 (renin release): dopamine activates adrenergic receptors and renin is a classic B1 effect. The trap is that low-dose dopamine engages its own dedicated D1 receptor before adrenergic receptors activate. Think of a dopamine infusion as a volume dial sweeping through three radio stations: at low volume (1-3 mcg/kg/min) it plays D1 renal vasodilation, at medium volume (5-10) it switches to B1 cardiac, at high volume (over 10) it locks onto alpha-1 vasoconstriction. The dial position, not the drug, determines the receptor. C is correct. At low doses (1-3 mcg/kg/min), dopamine preferentially activates D1 receptors in renal and mesenteric vasculature → vasodilation → increased renal blood flow → increased GFR → more urine. Higher doses: β1 kicks in (5-10 mcg/kg/min). Very high doses: α1 dominates (>10 mcg/kg/min). Note: clinical trials have not confirmed mortality benefit from "renal-dose" dopamine. Break it down: Dopamine dose-response → Low (1-3 mcg/kg/min): D1 renal vasodilation → Medium (5-10): β1 cardiac → High (>10): α1 vasoconstriction. Dose determines receptor.

Tempting to pick A (alpha-1 block): propranolol is such a potent drug it seems to block everything. The trap is that propranolol is a pure beta-blocker with zero alpha activity. Think of hypoglycemia alarms as two separate systems on different fuse boxes: the adrenergic alarm (tachycardia, tremor, anxiety) and the cholinergic sweating alarm. Propranolol cuts only the adrenergic fuse box. The cholinergic sweating circuit is wired to a completely separate panel that beta-blockers cannot reach. B is correct. Hypoglycemia warning signs are adrenergic: tremor (β2 skeletal muscle), tachycardia (β1 cardiac), anxiety (CNS beta), glycogenolysis (β2 liver). Propranolol is non-selective → blocks ALL beta receptors → all these signs are blunted. BUT sweating is cholinergic (not adrenergic) → NOT blocked by propranolol → diaphoresis persists as the only warning. This is "masked hypoglycemia" · dangerous in insulin-dependent diabetics. Break it down: Non-selective β-blockers mask hypoglycemia symptoms (tachycardia, tremor, anxiety) but NOT sweating (cholinergic). Diaphoresis without tachycardia = β-blocker masking hypoglycemia.

Tempting to pick B1 blockade: the heart slows when you stand and BP falls, so a cardiac mechanism seems right. The trap is tamsulosin has no B1 activity at all. Think of the standing vasoconstriction reflex as a hydraulic gate that normally squeezes blood upward when you rise: alpha-1 is the gate mechanism. Tamsulosin locks the gate open (blocks alpha-1 permanently), so gravity pools blood in the legs with no reflex squeeze to push it back up. A is correct. Tamsulosin is a selective α1 blocker. On standing, gravity pools blood in the legs. Normally: sympathetic system fires → NE → α1 activation → peripheral vasoconstriction → BP maintained. With α1 blocked: this reflex can't happen → BP drops → orthostatic hypotension. More pronounced with first dose and volume depletion. Non-uroselective α1 blockers (prazosin) have worse first-dose phenomenon. Break it down: α1 blockers → orthostatic hypotension because the standing reflex vasoconstriction can't fire. First-dose phenomenon = worst with prazosin. Tamsulosin (uroselective) has less BP effect but still causes it.

Tempting to start with a beta-blocker: tachycardia is the visible threat and propranolol controls it quickly. The trap is that blocking beta before alpha removes B2-mediated vasodilation (the only partial counterbalance) while leaving alpha-1 vasoconstriction fully unopposed. Think of it like closing a pressure release valve before shutting off the main supply line: the pressure explodes. Shut off alpha first (the main line), then close the beta valve. C is correct. Pheochromocytoma dumps massive catecholamines. The clue: alpha activation drives extreme vasoconstriction and HTN crisis. The chain: if you block beta FIRST, you remove β2-mediated vasodilation in skeletal muscle while leaving α1 vasoconstriction unopposed → BP spikes higher. So you alpha-block first (phenoxybenzamine = irreversible non-selective alpha antagonist), wait several days for adequate blockade and volume expansion, THEN add beta-blocker for residual tachycardia. Break it down: Pheochromocytoma prep = ALPHA before BETA. Phenoxybenzamine first. Add beta-blocker only after adequate alpha blockade. "Beta-blocking a pheo first" kills patients.

Tempting to pick B1 since albuterol causes tachycardia and is sometimes used in high-dose cardiac protocols. The trap is that tremor and hypokalemia are both B2 effects in non-pulmonary organs. Think of B2 receptors as the same lock on multiple doors in a building: the lung door (bronchodilation, intended), the skeletal muscle door (tremor, extra), and the Na/K pump door (K+ driven into cells, hypokalemia). One key opens all three simultaneously. D is correct. Albuterol is a β2 agonist. β2 receptors are NOT just in lungs. They are also in skeletal muscle (causing fine tremor) and on the Na/K-ATPase pump (driving potassium INTO cells, lowering serum K+). This is why high-dose albuterol can be used to treat hyperkalemia. Same receptor, different tissues, predictable side effects. Break it down: β2 agonist side effects = tremor (skeletal muscle β2) + hypokalemia (Na/K-ATPase shift). Same drug, same receptor, different organ.

Tempting to pick alpha-1 antagonism: it relaxes the bladder neck (tamsulosin does exactly that for BPH). The trap is that alpha-1 block in the bladder neck reduces outflow resistance but does not relax the detrusor itself. Think of the bladder as a balloon with a drawstring at the bottom: alpha-1 antagonism loosens the drawstring, but B3 agonism makes the entire balloon wall more stretchy so it fills further before the urgency signal fires. D is correct. Mirabegron is a β3 agonist. β3 lives in adipose tissue (lipolysis) and the detrusor muscle. Stimulating β3 in detrusor → relaxation → bladder fills more before urgency → fewer urgency episodes. Because β3 is not muscarinic, it avoids dry mouth, urinary retention risk in BPH, and confusion (key wins in elderly patients who fail anticholinergics). Break it down: Overactive bladder + can't tolerate anticholinergic = mirabegron (β3 agonist). β3 = adipose lipolysis + detrusor relaxation. No antimuscarinic side effects.